Ads
related to: t-cell therapy- Using DLL3 Approaches
Targeting DLL3 Through T-cell
Engager Technology In SCLC
- T-Cell Engager Technology
See How Engaging T-Cells With DLL3
Can Play An Important Role In SCLC
- About SC Lung Cancer
Oncologists: Discover The Potential
Of T-Cell Engager Technology
- SCLC Resources For HCPs
Download A DLL3 Factsheet & View
Patient Testimonial Videos
- Using DLL3 Approaches
Search results
Coya Therapeutics Reports First Quarter 2024 Financial Results
Guru Focus· 5 days agoOn May 9, 2024, Coya Therapeutics Inc (COYA, Financial), a trailblazer in biologics for enhancing regulatory T cell function, disclosed its financial outcomes ...
Precigen Reports First Quarter 2024 Financial Results and Business Updates
Morningstar· 14 hours ago– Pivotal Phase 2 study data of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis to be presented at the 2024 ASCO Annual Meeting as a late-breaking oral presentation on June 3rd – – Company to host a conference
Iovance Biotherapeutics Inc (IOVA) Q1 2024 Earnings: Aligns with EPS Projections Amidst Strong ...
GuruFocus.com via Yahoo Finance· 5 days agoInc (NASDAQ:IOVA), a trailblazer in the development of novel cancer treatments, disclosed its...
Fate Therapeutics, Inc. (NASDAQ:FATE) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 2 days agoFate Therapeutics, Inc. (NASDAQ:FATE) Q1 2024 Earnings Call Transcript May 11, 2024 Fate...
Celularity Inc. (NASDAQ:CELUW) Short Interest Up 34.4% in April
ETF DAILY NEWS· 5 hours agoCelularity Inc. (NASDAQ:CELUW – Get Free Report) was the recipient of a significant increase in short interest in the month of April. As of April 30th, there was short interest totalling 161,700 ...
Gene therapy trials deliver double win
Nature· 6 days agoFinal results of two studies — whose preliminary data led to regulatory approval of the gene therapy exagamglogene autotemcel — describe highly effective...
Fate Therapeutics Inc (FATE) Q1 2024 Earnings: Mixed Financial Performance Amid Clinical ...
GuruFocus.com via Yahoo Finance· 5 days agoResearch and Development: Progress noted in clinical trials, including treatment of first patient in FT819 CAR T-cell therapy for autoimmunity ...
Nature Immunology spotlights Alchemab's cancer therapy potential
BioPharma-Reporter· 20 hours agoThe senior author Rachael Bashford-Rogers is a co-founder of Alchemab and the paper was a...
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024
WRBL Columbus· 14 hours ago...proprietary allogeneic CAR-T platform to develop cell therapies targeting solid tumors Generated $95 million in milestone and upfront payments to-date in 2024, including $50 million from Astellas collaboration and $45 million from continued execution in the Company's CAR-T partnership with Roche...
Study highlights need for cell-type-specific therapies in treatment of HIV
Medical Xpress· 2 days agoResearchers from the University of Illinois have demonstrated the importance of cell-type-specific...
Ads
related to: t-cell therapy